Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants

David I. Bernstein, David A. Sack, Keith Reisinger, Edward Rothstein, Richard L. Ward

Research output: Contribution to journalArticle

Abstract

Rotavirus vaccine development is a high priority. The association between the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new vaccines. In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be safe and effective; 184 of the 215 healthy infants initially enrolled in this trial were followed for a second year. Vaccine efficacy during the second year was 59% (P = .047). For the 2 years of observation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus illnesses requiring medical intervention (P < .001 for each). These encouraging results have led to continued evaluation, in several countries, of a vaccine candidate derived from strain 89-12.

Original languageEnglish (US)
Pages (from-to)1487-1489
Number of pages3
JournalJournal of Infectious Diseases
Volume186
Issue number10
DOIs
StatePublished - Nov 15 2002

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants'. Together they form a unique fingerprint.

  • Cite this